3-Hydroxyphencyclidine (3-HPC), a derivative of phencyclidine (PCP), is increasingly attracting clinical scrutiny due to initial evidence suggesting unique pharmacological characteristics. Preliminary studies demonstrate that 3-HPC may display independent responses on the brain structure, arguably playing a role to some of the unanticipated symptom